ClinicalTrials.gg
TerminatedNCT01398852Updated Jun 29, 2022Results posted

Safety and Effectiveness Study of the VEGA UV-A System for Cross-linking in Eyes With Keratoconus and Ectasia

A Phase 3 interventional study of Riboflavin and VEGA UV-A Illumination System in Keratoconus and Ectasia, sponsored by Topcon Medical Systems, Inc.. Terminated at 13 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2022-06-29.

Sponsored by Topcon Medical Systems, Inc. (part of Topcon Corporation) · Phase 3, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
500
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing riboflavin in Keratoconus — 5 open to participants now, 8 under way, 7 of them phase 3. Riboflavin · Keratoconus.

Enrollment
5th of 23
500 · median 170
Started
2010
with 5 others
Phase 3
12 of 23
3 open now
Registered
8th of 23
by date

Among the 23 studies testing riboflavin in Keratoconus, this one is the 5th largest by enrollment, is one of 6 that started in 2010, is one of 12 in phase 3, and was the 8th registered.

Keratoconus

313 studies on the registry are indexed under Keratoconus; 56 are open to participants now.

Browse Keratoconus studies →

Open to participants now

5 of the 23 studies testing riboflavin in Keratoconus are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

About riboflavin

Riboflavin: first FDA approval 1953 (M.V.I.-12 ADULT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Keratoconus studies recruiting now, 21 (57%) set no upper age limit and 11 (30%) stop at 75 or younger; 17 take children under 18; 15 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing riboflavin in Keratoconus, or all of them as a file.
02

Study summary

The purpose of this research study is to evaluate the long tern safety and effectiveness of cross-linking in eyes with keratoconus and ectasia.

03

Conditions studied

  • Keratoconus and Ectasia
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 12 years of age or older
  • Diagnosis of Keratoconus or Ectasia
  • Central or Inferior steepening on the Pentacam map
  • Topography consistent with Keratoconus or Ectasia
  • BSCVA 20/20 or worse
  • Removal of contact lenses for required period of time
  • Signed written
  • Willingness and ability to comply with schedule for follow up visits

Exclusion criteria

Exclusion Criteria

  • For Keratoconus, a history of previous corneal surgery
  • Corneal pachymentry equal to or greater and 400
  • Previous ocular condition in the eyes to be treated that may predispose the eye for future complications
  • A history of chemical injury or delayed healing
  • Pregnancy
  • A known sensitivity to the study medications
  • Nystagmus or any other condition that would prevent a steady gaze during treatment or other diagnostic tests
  • Presence or history of any other condition or finding that makes the patient unsuitable as a candidate
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
500 participants (actual)

Study arms

  • Experimental
    CXL Treatment

    All eyes to be treated with riboflavin and UV light

    Drug: Riboflavin · Device: VEGA UV-A Illumination System

Interventions

  • Riboflavin is a solution that will be delivered to the treatment area

  • DeviceVEGA UV-A Illumination System

    This is a portable electronic device designed to deliver a dose of UV-A light to the treatment area

06

What researchers measure

Primary outcomes

  1. Changes in Corneal Curvature

    Time frame: 24 MO

07

Results

Posted Mar 4, 2013

Participant flow

The recruitment period started December 2010 and ended June 2012 at medical clinics throughout the country.

Participant flow — Overall Study
MilestoneCXL Treatment
Started372
Completed0
Not completed372

Outcome measures

PrimaryChanges in Corneal Curvature
Time frame:
24 MO

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CXL Treatment—0/372 (0%)0/372 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)CXL Treatment
<=18 yearsNA
Between 18 and 65 yearsNA
>=65 yearsNA
Age, Continuous
Age, Continuous(years)CXL Treatment
MeanNA ± NA
Sex: Female, Male
Sex: Female, Male(Participants)CXL Treatment
FemaleNA
MaleNA
Region of Enrollment
Region of Enrollment(participants)CXL Treatment
United States372
08

Study locations

13 sites
  • Barnet Dulaney Perkins Eye Center
    Phoenix, Arizona, United States
  • Woolfson Eye Institute
    Atlanta, Georgia, United States
  • Massachusetts Eye And Ear Infirmary
    Boston, Massachusetts, United States
  • Minnesota Eye Consultants
    Bloomington, Minnesota, United States
  • Laser and Corneal Surgery Assoc. PC
    New York, New York 10022, United States
  • Mt Sinai Hospital
    New York, New York, United States
  • Pamel Vision & Laser Group
    New York, New York, United States
  • Cleveland Clinic-Cole Eye Institute
    Cleveland, Ohio 44195, United States
  • ReVision Advanced Laser Eye Center
    Columbus, Ohio 43240, United States
  • OSU Department of Ophthalomogy
    Columbus, Ohio, United States
  • Dell Laser Consultants
    Austin, Texas, United States
  • Slade and Baker Vision Center
    Houston, Texas, United States
  • The Eye Institute of Utah
    Salt Lake City, Utah 84107, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2010, a primary completion of Jul 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2013, 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2011
First posted
Jul 21, 2011
Start
Dec 2010
Primary completionActual
Jul 2012
CompletionActual
Jul 2012
Results first posted
Mar 4, 2013
Last update
Jun 29, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01398852
Responsible party
Sponsor
First posted
Jul 21, 2011
Start date
Dec 2010
Primary completion
Jul 2012
Completion
Jul 2012
Results posted
Mar 4, 2013
Last update
Jun 29, 2022

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Riboflavin

Start the discussion